Relmada Therapeutics (RLMD) Assets Average (2013 - 2026)

Relmada Therapeutics (RLMD) has 14 years of Assets Average data on file, last reported at $164.7 million in Q1 2026.

• On a quarterly basis, Assets Average rose 348.13% year-over-year to $164.7 million in Q1 2026; TTM through Mar 2026 was $164.7 million, a 348.13% increase from a year earlier, with the FY2025 full-year figure at $69.9 million, down 2.48% from the prior year.
• Assets Average for Q1 2026 stood at $164.7 million, up from $54.4 million in the prior quarter.
• Over the last five years, Assets Average for RLMD reached as high as $224.6 million in Q1 2022 and fell as low as $18.0 million in Q3 2025.
• Historically, Assets Average has averaged $111.2 million across 5 years, with a median of $103.4 million in 2023.
• Across the five-year window, Assets Average slumped 71.6% in 2025 and soared 348.13% in 2026, its largest moves.
• Year by year, Assets Average stood at $170.0 million in 2022, then sank by 39.21% to $103.4 million in 2023, then slumped by 50.87% to $50.8 million in 2024, then increased by 7.23% to $54.4 million in 2025, then soared by 202.5% to $164.7 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $164.7 million in Q1 2026, $54.4 million in Q4 2025, and $18.0 million in Q3 2025.